The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo Nordisk ...

Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight. If approved, ...

The Wegovy pill is FDA-approved to reduce excess body weight and maintain weight reduction long-term in adults who have ...

The Wegovy pill is expected to hit the market in January, joining injectable GLP-1 drugs that have transformed obesity treatment. One form you swallow, the other you inject. What else is different?

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...

The FDA on Monday approved a daily pill version of Novo Nordisk’s Wegovy, making it the first oral GLP-1 obesity treatment ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy (R) pill, the first oral GLP-1 medicine for obesity in the US. (3) Wegovy (R) pill is used ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.

The FDA’s approval of a GLP-1 weight-loss pill could make these drugs easier to access and harder to ignore. People who are squeamish about needles for administering GLP-1 weight-loss drugs will soon ...

Imagine this scenario: You’ve been diligently working toward your weight management goals, and your healthcare team has prescribed Wegovy (semaglutide). You’re excited, you’ve done your research, and ...

The FDA approved Novo Nordisk’s once-daily Wegovy pill, making it the first oral GLP-1 weight loss drug to reach the U.S.